ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1686

Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy

Eugen Feist1, Saeed Fatenejad2, Sergey Grishin3, Elena Korneva3, Michael Luggen4, Evgeniy Nasonov5, Mikhail Samsonov6 and Roy Fleischmann7, 1Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 2SFC Medica, LLC, Charlotte, NC, 3R-Pharm, Moscow, Russia, 4Cincinnati Rheumatic Disease Study Group, Inc., and University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, 5V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, 6RPharm, Moscow, Russia, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2021

Keywords: Biologicals, olokizumab, RCT, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Olokizumab (OKZ), a humanized monoclonal antibody targeting IL-6, was studied in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) (NCT02760368, NCT02760407) [1]. Here we present the results of a global phase III; randomized placebo (PBO) controlled clinical trial (RCT) in patients with RA with an incomplete response to tumor necrosis factor inhibitors (TNFi).

Methods: Patients with active RA who had failed TNFi (NCT02760433) were enrolled in this double-blind RCT conducted in 11 countries including the USA. Patients were randomized in a 2:2:1 ratio to receive subcutaneous (SC) injections of OKZ 64 mg every 2 weeks (q2w), OKZ 64 mg once every 4 weeks (q4w) or PBO, plus MTX. At week (Wk) 16, all subjects in the PBO group were randomized in a 1:1 ratio to receive either OKZ regimens. After Wk 24, subjects could continue in an open-label study or entered a Safety Follow-Up Period for another 20 weeks.

The primary endpoint was the percent of patients achieving an American College of Rheumatology 20 response rate (ACR20) at Wk 12. Secondary endpoints at WK 12 included the percentage of subjects achieving a Disease Activity Score 28-joint count – C-reactive protein (DAS28-CRP) < 3.2, improvement of physical ability from baseline to Wk 12 measured by the Health Assessment Questionnaire-Disability Index (HAQ - DI), ACR50 response and percentage of subjects achieving a Clinical Disease Activity Index (CDAI) ≤2.8. Safety outcomes were assessed. A hierarchical statistical scheme was pre-defined to control for multiple comparisons.

Results: 368 subjects were randomized and 320 patients (87%) completed the 24-week treatment period. Baseline characteristics were comparable across arms (Table 1).

Both regimens of OKZ were statistically significantly better than PBO in achieving the primary endpoint (Table 2). The efficacy of OKZ was maintained to Wk 24.

Overall incidences of treatment-emergent adverse events (TEAEs) were 65.5% in OKZ q2w, 65.0% in OKZ q4w and 50.7% in PBO. Subsequent randomization of PBO arm to OKZ at Wk 16 did not substantially change the TEAE incidence rate per treatment group: 64.3% in any OKZ q2w and 59.7% in any OKZ q4w. The majority of TEAEs in all groups were of mild or moderate severity.

Incidence of treatment-emergent serious adverse events (TESAEs) were: 12 (7.0%) in subjects treated with OKZ q2w; 6 (3.2%) in subjects treated with OKZ q4w (Table 3).

The most frequently reported TESAEs across all treatment groups were infections and infestations: 2 (1.1%) in OKZ q4w group, 2 (1.2%) in OKZ q2w group.

No serious opportunistic infections including active tuberculosis, major adverse cardiovascular events, gastrointestinal perforations or deaths were reported.

Conclusion: In this global Phase III trial in patients with active RA inadequately controlled by TNFi, treatment with OKZ 64 mg q2w and OKZ 64 mg q4w plus MTX was associated with significant improvements in the signs and symptoms of RA compared to PBO plus MTX over a 24-week period.

Treatment with OKZ q2w and q4w in this difficult to treat population was generally well tolerated and was similar with the established safety profile of IL-6 inhibitors.

References:1. https://clinicaltrials.gov/ct2/home

Table 1. Demographic and Other Baseline Characteristics (intent-to-treat population). 1, 100% patients were on MTX; 2, upper limit of normal 6 mg/L; SD, standard deviation; BMI, body mass index; TJC, tender joint count; SJC, swollen joint count

Table 2. Key efficacy results (intent-to-treat population) NRI. NRI, non-responder imputation; LSM, least squares mean; respectively; 1, following the gate-keeping strategy, testing for both OKZ regimens was stopped after the HAQ-DI endpoint testing for formal comparison; SE, Standard Error.

Table 3. Number and percentage of TESAE (Safety Population). Adverse effects that occurred after the first administration of PBO and prior to any administration of OKZ at or after Week 16 are summarized as a TEAE under PBO.


Disclosures: E. Feist, R-Pharm, 2, 6, Abbvie, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, AB2Bio, 6, BMS, 6, Celgene, 6, Janssen, 6, Eli Lilly, 2, 5, 6, Medac, 6, MSD, 6, Roche/Chugai, 2, 5, 6, Sanofi, 6, Sobi, 6, UCB, 6; S. Fatenejad, R-Pharm, 2, 4, Pfizer, 9; S. Grishin, R-Pharm, 3; E. Korneva, R-Pharm, 3; M. Luggen, R-Pharm, 5, Abbvie, 5, Sun Pharmaceuticals, 5, Pfizer, 5, Novartis, 5, Eli Lilly, 5, GSK, 5, Genentech, 2, 5, 6, Nichi-Iko, 2, 5, 6, Amgen, 2, 5, 6; E. Nasonov, Eli Lilly, 2, Abbvie, 2, Pfizer, 2, Hoffmann-La Roche, 2, Biocad, 2, R-Pharm, 2; M. Samsonov, R-Pharm, 3; R. Fleischmann, AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, Celltrion, 2, 5, Eli Lilly, 2, 5, Genentech, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sanofi-Aventis, 2, 5, UCB, 2, 5, GSK, 2, 5, AstraZeneca, 2, 5, Bayer, 2, 5, Biogen, 5, Flexion, 2, 5, Galapagos, 5, Galvani, 2, 5, Gilead Sciences, 2, 5, Horizon, 5, Noven, 5, Samumed, 5, Scipher, 5, Selecta, 5, Teva Pharmaceuticals, 5, Viela, 5, Vorso, 5.

To cite this abstract in AMA style:

Feist E, Fatenejad S, Grishin S, Korneva E, Luggen M, Nasonov E, Samsonov M, Fleischmann R. Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-olokizumab-in-a-phase-iii-trial-of-patients-with-moderately-to-severely-active-rheumatoid-arthritis-inadequately-controlled-by-tnf-%ce%b1-inhibitor-therapy/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-olokizumab-in-a-phase-iii-trial-of-patients-with-moderately-to-severely-active-rheumatoid-arthritis-inadequately-controlled-by-tnf-%ce%b1-inhibitor-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences